Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05502341 |
|
Recruitment Status :
Recruiting
First Posted : August 16, 2022
Last Update Posted : April 5, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| HIV-1-infection | Drug: Bictegravir Drug: Lenacapavir Drug: BIC/LEN FDC Drug: Stable Baseline Regimen | Phase 2 Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 671 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | An Operationally Seamless Phase 2/3 Randomized, Open-label, Multicenter, Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Stable Baseline Regimen in Virologically Suppressed People With HIV-1 on Stable Complex Treatment Regimens |
| Actual Study Start Date : | August 16, 2022 |
| Estimated Primary Completion Date : | January 2026 |
| Estimated Study Completion Date : | November 2028 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Phase 2: Bictegravir (BIC) 75 mg + Lenacapavir (LEN) 25 mg
Participants will switch from their stable baseline regimen (SBR) to a regimen of BIC 75 mg + LEN 25 mg. Participants will receive a 2-day loading dose regimen of LEN 600 mg, in addition to the daily doses of BIC 75 mg + LEN 25 mg starting on Day 1 up to the end of randomized treatment (ERT) visit, participants will be treated for at least 24 weeks during the Randomized Period. Following Randomized Period, the participants will have an option to participate in an Extension Period to receive BIC/LEN 75 mg/50 mg fixed dose combination (FDC). |
Drug: Bictegravir
Tablets administered orally without regard to food
Other Name: GS-9883 Drug: Lenacapavir Tablets administered orally without regard to food
Other Name: GS-6207 |
|
Experimental: Phase 2: BIC 75 mg + LEN 50 mg
Participants will switch from their SBR to a regimen of BIC 75 mg + LEN 50 mg. Participants will receive a 2-day loading dose regimen of LEN 600 mg, in addition to the daily doses of BIC 75 mg + LEN 50 mg starting on Day 1 up to the ERT visit, participants will be treated for at least 24 weeks during the Randomized Period. Following Randomized Period, the participants will have an option to participate in an Extension Period to receive BIC/LEN 75 mg/50 mg FDC. |
Drug: Bictegravir
Tablets administered orally without regard to food
Other Name: GS-9883 Drug: Lenacapavir Tablets administered orally without regard to food
Other Name: GS-6207 |
|
Active Comparator: Phase 2: Stable Baseline Regimen (SBR)
Participants will continue with their SBR per prescription for up to the ERT visit, participants will be treated for at least 24 weeks during the Randomized Period. Following Randomized Period, the participants will have an option to participate in an Extension Period to receive BIC/LEN 75 mg/50 mg FDC. |
Drug: Stable Baseline Regimen
SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).
|
|
Experimental: Phase 3: BIC/LEN 75 mg/50 mg Fixed-dose Combination (FDC)
Participants will switch from their SBR to a regimen of BIC/LEN 75 mg/50 mg FDC. Participants will receive a 2-day loading dose regimen of LEN 600 mg, in addition to the daily doses of BIC/LEN 75 mg/50 mg FDC starting on Day 1 up to the ERT visit, participants will be treated for at least 48 weeks during the Randomized Period. Following Randomized Period, the participants will have an option to participate in an Extension Period to receive BIC/LEN 75 mg/50 mg FDC. |
Drug: BIC/LEN FDC
Tablets administered orally without regard to food |
|
Active Comparator: Phase 3: Stable Baseline Regimen
Participants will continue with their SBR per prescription for up to the ERT visit, participants will be treated for at least 48 weeks during the Randomized Period. Following Randomized Period, the participants will have an option to participate in an Extension Period to receive BIC/LEN 75 mg/50 mg FDC. |
Drug: Stable Baseline Regimen
SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).
|
- Phase 2: Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Determined by the US FDA-defined Snapshot Algorithm [ Time Frame: Week 24 ]
- Phase 3: Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm [ Time Frame: Week 48 ]
- Phase 2: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Determined by the US FDA-defined Snapshot Algorithm [ Time Frame: Week 24 ]
- Phase 2: Change From Baseline in CD4 Cell Count at Week 24 [ Time Frame: Baseline, Week 24 ]
- Phase 2: Percentage of Participants Experiencing Treatment-emergent Adverse Events (AEs) Through Week 24 [ Time Frame: First dose date up to Week 24 ]
- Phase 2: Pharmacokinetic (PK) Parameter: Cmax of Bictegravir (BIC) and Lenacapavir (LEN) at Steady State [ Time Frame: Day 1 up to Week 24 ]Cmax is defined as the maximum observed concentration of drug.
- Phase 2: PK Parameter: AUCtau of BIC and LEN at Steady State [ Time Frame: Day 1 up to Week 24 ]AUCtau is defined as the area under the concentration versus time curve over the dosing interval.
- Phase 2: PK Parameter: Ctau of BIC and LEN at Steady State [ Time Frame: Day 1 up to Week 24 ]Ctau is defined as the observed drug concentration at the end of the dosing interval.
- Phase 3: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm [ Time Frame: Week 48 ]
- Phase 3: Change From Baseline in CD4 Cell Count at Week 48 [ Time Frame: Baseline, Week 48 ]
- Phase 3 (BIC/LEN 75 mg/50 mg FDC): Proportion of Participants from With HIV-1 RNA ≥ 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot Algorithm [ Time Frame: Week 96 ]
- Phase 3 (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 96 [ Time Frame: Baseline, Week 96 ]
- Phase 3: Percentage of Participants Experiencing Treatment-emergent AEs Through Week 48 [ Time Frame: First dose date up to Week 48 ]
- Phase 3 (BIC/LEN 75 mg/50 mg FDC): Proportion of Participants from Experiencing Treatment-emergent AEs Through Week 96 [ Time Frame: Week 96 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
- If plasma HIV-1 RNA measurements in the 6 months prior to screening are available, all levels must be < 50 copies/mL.
- At least one documented plasma HIV-1 RNA level measured between 6 and 12 months (± 2 months) prior to screening. This and any other HIV-1 RNA measurements documented in this period must be < 50 copies/mL
- Plasma HIV-1 RNA levels < 50 copies/mL at screening.
-
Currently receiving a complex antiretroviral (ARV) regimen due to previous viral resistance, or intolerance, or contraindication to existing single-tablet regimens (STR), and on this regimen for at least 6 months prior to the screening visit. The criteria to define a complex regimen in this study are as follows:
- A regimen containing a boosted protease inhibitor or a nonnucleos(t)ide reverse transcriptase inhibitor (NRTI) plus at least 1 other third agent (ie, an agent from a class other than NRTIs) (eg, bictegravir/emtricitabine/tenofovir alafenamide (coformulated; Biktarvy®)(BVY) + darunavir/cobicistat, BVY + etravirine), or
- A regimen of ≥ 2 pills/day, or a regimen requiring dosing more than once daily, or
- A regimen containing parenteral agent(s) (excluding a complete long-acting injectable regimen, such as intramuscular cabotegravir plus rilpivirine) as well as oral agents.
- No documented or suspected resistance to bictegravir (BIC).
- Estimated glomerular filtration rate ≥ 15 mL/min according to the Cockcroft-Gault formula for creatinine clearance (CLcr) who are not on renal replacement therapy.
Key Exclusion Criteria:
- Prior use of, or exposure to, lenacapavir (LEN)
- Active tuberculosis infection
- Chronic hepatitis B virus (HBV) infection
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05502341
| Contact: Gilead Clinical Study Information Center | 1-833-445-3230 (GILEAD-0) | GileadClinicalTrials@gilead.com |
Show 87 study locations
| Study Director: | Gilead Study Director | Gilead Sciences |
| Responsible Party: | Gilead Sciences |
| ClinicalTrials.gov Identifier: | NCT05502341 |
| Other Study ID Numbers: |
GS-US-621-6289 2022-500929-33 ( Other Identifier: European Medicines Agency ) DOH-27-052023-8574 ( Other Identifier: South African Clinical Trial Registry ) |
| First Posted: | August 16, 2022 Key Record Dates |
| Last Update Posted: | April 5, 2024 |
| Last Verified: | April 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |